The molecular biology of colorectal carcinoma and its implications: A review

Surgeon

Volumn 9, Issue 4, 2011, Pages 200-210

  Harrison, Sanjay ^a   Benziger, Harrison ^b  

^a SUNDERLAND ROYAL HOSPITAL   (United Kingdom)

^b EAST KENT HOSPITALS UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Colorectal carcinoma; Genetics; Molecular biology; Mutations

Indexed keywords

BIOLOGICAL MARKER;

COLORECTAL TUMOR; HUMAN; MASS SCREENING; METABOLISM; METHODOLOGY; MOLECULAR BIOLOGY; MORBIDITY; REVIEW; UNITED KINGDOM;

BIOLOGICAL MARKERS; COLORECTAL NEOPLASMS; GREAT BRITAIN; HUMANS; MASS SCREENING; MOLECULAR BIOLOGY; MORBIDITY;

EID: 79958778350     PISSN: 1479666X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surge.2011.01.011     Document Type: Review

References (124)

1. Kemp Z., Thirlwell C., Sieber O., Silver A., Tomlinson I. An update on the genetics of colorectal cancer. Hum Mol Genet 2004 Oct 1, 13(2):R177-R185.
2. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010 Jun 17.
3. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigensis. Cell 1990 Jun 1, 61(5):759-767.
4. Leslie A., Carey F.A., Pratt N.R., Steele R.C. The colorectal adenoma-carcinoma sequence. Br J Surg 2002, 89:845-860.
5. Wei E.K., Wolin K.Y., Colditz G.A. Time course of risk factors in cancer etiology and progression. J Clin Oncol 2010 Sep 10, 28(26):4052-4057.
6. Perea J., Alvaro E., Rodriguez Y., Gravalos C., Sanchez T.E., Rivera B., et al. Approach to early onset colorectal cancer: clinicopathological, familial, molecular and immunohistochemical characteristics. Endoscopy 2010, 42(Suppl. 2):E186-E187.
7. Worthley D.L., Leggett B.A. Colorectal cancer: molecular features and clinical opportunities. Clin Biochem Rev 2010 May, 31(2):31-38.
8. Grady W.M., Carethers J.M. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 2008, 135:1079-1099.
9. Walter A., Houlston R., Tomlinson I. Association between chromosomal instability and prognosis in colorectal cancer: a meta analysis. Gut 2008, 57:941-950.
10. Pritchard C.C., Grady W.M. Colorectal cancer molecular biology moves into clinical practice. Gut 2011 Jan, 60(1):116-129.
11. Rowan A., Halford S., Gaasenbeek M., Kemp Z., Sieber O., Volikos E., et al. Refining molecular analysis in the pathways of colorectal carcinogenesis. Clin Gastroenterol Hepatol 2005 Nov, 3(11):1115-1123.
12. Bellam N., Pasche B. TGF beta signaling alterations and colon cancer. Cancer Treat Res 2010, 155:85-103.
13. Chow E., Macrae F. A review of juvenile polyposis syndrome. J Gastroenterol Hepatol 2005 Nov, 20(11):1634-1640.
14. Jiang Y., Kimchi E.T., Staveley O.C., Cheng H., Ajani J.A. Assessment of K-ras mutation: a step toward personalised medicine for patients with colorectal cancer. Cancer 2009 Aug 15, 115(16):3609-3617.
15. Phelps R.A., Chidester S., Dehghanizadeh S., Phelps J., Sandoval I.T., Rai K. A two-step model for colon adenoma initiation and progression caused by APC loss. Cell 2009 May 15, 137(4):623-634.
16. Sillars-Hardebol A.H., Carvalho B., de Wit M., Postma C., Delis-Van Diemen P.M., Mongera S., et al. Identification of key genes for carcinogenic pathways associated with colorectal adenoma-to-carcinoma progression. Tumour Biol 2010 Apr, 31(2):89-96.
17. Kennell J., Cadigan K.M. APC and beta-catenin degradation. Adv Exp Med Biol 2009, 656:1-12.
18. Sena P., Saviano M., Monni S., Losi L., Roncucci L., Marzona L., et al. Subcellular localization of beta-catenin and APC proteins in colorectal preneoplastic and neoplastic lesions. Cancer Lett 2006 Sep 28, 241(2):203-212.
19. Malumbres M., Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer 2003 Jun, 3(6):459-465.
20. Hatzivassiliou G., Song K., Yen I., Brandhuber B.J., Anderson D.J., Alvarado R., et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010 Mar 18, 464(7287):431-435.
21. Saif M.W., Shah M. K-ras mutations in colorectal cancer: a practice changing discovery. Clin Adv Heamtol Oncol 2009 Jan, 7(1):45-53.
22. Yuen S.T., Davies H., Chan T.L., Ho J.W., Bignell G.R., Cox C., et al. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res 2002 Nov 15, 62(22):6451-6455.
23. Wang J.Y., Wang Y.H., Jao S.W., Lu C.Y., Kuo C.H., Hu H.M., et al. Molecular mechanisms underlying the tumorigensis of colorectal adenomas: correlation to activated K-ras oncogene. Oncol Rep 2006 Dec, 16(6):1245-1252.
24. Velho S., Moutinho C., Cirnes L., Albuquerque C., Hamelin R., Schmitt F., et al. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis?. BMC Cancer 2008 Sep 9, 8:255.
25. Jancík S., Drábek J., Radzioch D., Hajdúch M. Clinical relevance of KRAS in human cancers. J Biomed Biotechnol 2010, 2010:150960.
26. Boland C.R., Shin S.K., Goel A. Promoter methylation in the genesis of gastrointestinal cancer. Yonsei Med J 2009 Jun 30, 50(3):309-321.
27. Kim J.C., Choi J.S., Roh S.A., Cho D.H., Kim T.W., Kim Y.S. Promoter methylation of specific genes is associated with the phenotype and progression of colorectal adenocarcinomas. Ann Surg Oncol 2010 Jul, 17(7):1767-1776.
28. Feltus F.A., Lee E.K., Costello J.F., Plass C., Vertino P.M. DNA motifs associated with aberrant CpG island methylation. Genomics 2006 May, 87(5):572-579.
29. Lee S., Cho N.Y., Yoo E.J., Kim J.H., Kang G.H. CpG island methylator phenotype in colorectal cancers: comparison of the new and classic CpG island methylator phenotype marker panels. Arch Pathol Lab Med 2008 Oct, 132(10):1657-1665.
30. Teodoridis J.M., Hardie C., Brown R. CpG island methylator phenotype (CIMP) in cancer: causes and implications. Cancer Lett 2008 Sep 18, 268(2):177-186.
31. Boland C.R., Goel A. Microsatellite instability in colorectal cancer. Gastroenterology 2010 Jun, 138(6):2073-2087.
32. Vilar E., Gruber S.B. Microsatellite instability in colorectal cancer - the stable evidence. Nat Rev Clin Oncol 2010 Mar, 7(3):153-162.
33. Shah S.N., Hile S.E., Eckert K.A. Defective mismatch repair, microsatellite mutation bias and variability in clinical cancer phenotypes. Cancer Res 2010 Jan 15, 70(2):431-435.
34. Poulogiannis G., Frayling I.M., Arends M.J. DNA mismatch repair deficiency in sporadic colorectal cancer and Lynch Syndrome. Histopathology 2010 Jan, 56(2):167-179.
35. Bellizzi A.M., Frankel W.L. Colorectal cancer due to deficiency in DNA mismatch repair function: a review. Adv Anat Pathol 2009 Nov, 16(6):405-417.
36. Auclair J., Vaissiere T., Desseigne F., Lasset C., Bonadona V., Giraud S., et al. Intensity dependent constitutional MLH1 promoter methylation leads to early onset of colorectal cancer by affecting both alleles. Genes Chromosomes Cancer 2011 Mar, 50(3):178-185.
37. Walther A., Johnstone E., Swanton C. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 2009, 9:489-499.
38. Bacher J.W., Flanagan L.A., Smalley R.L. Development of a fluorescent multiplex assay for detection of MSI high tumours. Dis Markers 2004, 20:237-250.
39. Guastadisegni C., Colafranceschi M., Ottini L., Dogliotti E. Microsatellite instability as a marker of prognosis and response to therapy: a meta analysis of colorectal cancer survival data. Eur J Cancer 2010 Oct, 46(15):2788-2798.
40. Sheffer M., Bacolod M.D., Zuk O., Giardina S.F., Pincas H., Barany F., et al. Association of survival and disease progression with chromosomal instability: a genomic exploration of colorectal cancer. Proc Natl Acad Sci 2009 Apr 28, 106(17):7131-7136.
41. Leggett B., Whitehall V. Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology 2010 Jun, 138(6):2088-2100.
42. Farris A.B., Misdraji J., Srivastava A. Sessile serrated adenoma: challenging discrimination from other serrated colonic polyps. Am J Surg Pathol 2008, 32:30-35.
43. Torlakovic E.E., Gomez J.D., Driman D.K. Sessile serrated adenoma (SSA) vs traditional serrated adenoma (TSA). Am J Surg Pathol 2008, 32:21-29.
44. O'Brien M.J., Yang S., Mack C., Xu H., Huang C.S., Mulcahy E., et al. Comparison of microsatellite instability, CpG island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end points. Am J Surg Pathol 2006 Dec, 30(12):1491-1501.
45. Yang S., Farraye F.A., Mack C., Posnik O., O'Brien M.J. BRAF and KRAS mutations in hyperplastic polyps and serrated adenomas of the colorectum: relationship to histology and CpG island methylation status. Am J Surg Pathol 2004 Nov, 28(11):1452-1459.
46. Worthley D.L. Serrated neoplasia of the colorectum. World J Gastroenterol 2007 July 28, 13(28):3792-3798.
47. Sandmeier D., Benhattar J., Martin P., Bouzourene H. Serrated polyps of the large intestine: a molecular study comparing sessile serrated adenomas and hyperplastic polyps. Histopathology 2009 Aug, 55(2):206-213.
48. Vakiani E., Yantiss R.K. Pathologic features and biologic importance of colorectal serrated polyps. Adv Anat Pathol 2009 Mar, 16(2):79-91.
49. Pratilas C.A., Solit D.B. Targeting the mitogen activated protein kinase pathway: physiological feedback and drug response. Clin Cancer Res 2010 Jul 1, 16(13):3329-3334.
50. Minoo P., Moyer M.P., Jass J.R. Role of BRAF-V600E in the serrated pathway of colorectal tumourigenesis. J Pathol 2007 Jun, 212(2):124-133.
51. Welbrock C., Hurlstone A. BRAF as therapeutic target in melanoma. Biochem Pharmacol 2010 Sep 1, 80(5):561-567.
52. Nagasaka T., Koi M., Kloor M. Mutations in both KRAS and BRAF may contribute to the methylator phenotype in colon cancer. Gastroenterology 2008, 134:1950-1960.
53. Chan T.L., Zhao W., Leung S.Y., Yuen S.T. BRAF and KRAS mutations in colorectal hyperplastic polyps and serrated adenomas. Cancer Res 2003, 63:4878-4881.
54. Young J., Jenkins M., Parry S., Young B., Nancarrow D., English D., et al. Serrated pathway to colorectal cancer in the population: genetic consideration. Gut 2007, 56:1453-1459.
55. Terzic J., Grivennikov S., Karin E., Karin M. Inflammation and colon cancer. Gastroenterology 2010 Jun, 138(6):2101-2114.
56. Harpaz N., Polydorides A.D. Colorectal dysplasia in chronic inflammatory bowel disease: pathology, clinical implications and pathogenesis. Arch Pathol Lab Med 2010 Jun, 134(6):876-895.
57. Westbrook A.M., Szakmary A., Schiestl R.H. Mechanisms of intestinal inflammation and development of associated cancers: lessons learned from mouse models. Mutat Res 2010 Jul-Sep, 705(1):40-59.
58. Zisman T.L., Rubin D.T. Colorectal cancer and dysplasia in inflammatory bowel disease. World J Gastroenterol 2008 May 7, 14(17):2662-2669.
59. Kitamura T., Itoh M., Noda T., Matsuura M., Wakabayashi K. Combined effects of cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on intestinal tumorigenesis in adenomatous polyposis coli gene knockout mice. Int J Cancer 2004 Apr 20, 109(4):576-580.
60. Wang D., Dubois R.N. Prostaglandins and cancer. Gut 2006 Jan, 55(1):115-122.
61. Doherty G.A., Byrne S.M., Molloy E.S., Malhotra V., Austin S.C., Kay E.W., et al. Proneoplastic effects of PGE2 mediated by EP4 receptor in colorectal cancer. BMC Cancer 2009 Jun 26, 9:207.
62. Watanabe K., Kawamori T., Nakatsugi S., Ohta T., Ohuchida S., Yamamoto H., et al. -Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res 1999 Oct 15, 59(20):5093-5096.
63. Mutoh M., Watanabe K., Kitamura T., Shoji Y., Takahashi M., Kawamori T., et al. Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. Cancer Res 2002 Jan 1, 62(1):28-32.
64. Niho N., Mutoh M., Kitamura T., Takahashi M., Sato H., Yamamoto H., et al. Suppression of azoxymethane-induced colon cancer development in rats by a prostaglandin E receptor EP1-selective antagonist. Cancer Sci 2005 May, 96(5):260-264.
65. Banu N., Buda A., Chell S., Elder D., Moorghen M., Paraskeva C., et al. Inhibition of COX-2 with NS-398 decreases colon cancer cell motility through blocking epidermal growth factor receptor transactivation: possibilities for combination therapy. Cell Prolif 2007 Oct, 40(5):768-779.
66. Seno H., Oshima M., Ishikawa T.O., Oshima H., Takaku K., Chiba T., et al. Cyclooxygenase 2- and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc(Delta716) mouse intestinal polyps. Cancer Res 2002 Jan 15, 62(2):506-511.
67. Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol 2009 Dec, 1(6). a001651.
68. Thu Y.M., Richmond A. NF-κB inducing kinase: a key regulator in the immune system and in cancer. Cytokine Growth Factor Rev 2010 Aug, 21(4):213-226.
69. Balkwill F. TNF alpha in promotion and progression of cancer. Cancer Metastasis Rev 2006, 25:409-416.
70. Szlosarek P., Charles K.A., Balkwill F.R. Tumour necrosis factor alpha as a tumour promoter. Eur J Cancer 2006, 42:745-750.
71. Popivanova B.K., Kitamura K., Wu Y., Kondo T., Kagaya T., Kaneko S., et al. Blocking TNF alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest 2008, 118:560-570.
72. Fiorino G., Rovida S., Correale C., Malesci A., Danese S. Emerging biologics in the treatment of inflammatory bowel disease: what is around the corner?. Curr Drug Targets 2010 Feb, 11(2):249-260.
73. Testro A.G., Visvanathan K. Toll like receptors and their role in gastrointestinal disease. J Gastroenterol Hepatol 2009 Jun, 24(6):943-954.
74. Huang B., Zhao J., Li H., He K.L., Chen Y., Chen S.H., et al. Toll like receptors on tumour cells facilitate evasion of immune surveillance. Cancer Res 2005, 65:9108.
75. Fukata M., Abreu M.T. Role of Toll like receptors in gastrointestinal malignancies. Oncogene 2008, 27:234-243.
76. Goldstein N.S. - Serrated pathway and APC type colorectal polyps. Molecular-morphologic correlations, genetic pathways and implications for classification. Am J Pathol 2006, 125:146-153.
77. Kwong L.N., Dove W.F. APC and its modifiers in colon cancer. Adv Exp Med Biol 2009, 656:85-106.
78. Tighe A., Johnson V.L., Taylor S.S. Truncating APC mutations have dominant effects on proliferation, spindle checkpoint control, survival and chromosomal stability. J Cell Sci 2004, 117:6339-6353.
79. Goldstein N.S., Bhanot P., Odish E., Hunter S. Hyperplastic like colon polyps that preceded microsatellite unstable adenocarcinoma. Am J Clin Path 2003, 119:778-796.
80. Xu Y., Pasche B. TGFβ signalling alterations and susceptibility to colorectal cancer. Hum Mol Genet 2007 April 15, 16:R14-R20.
81. Akhurst R.J. TGF beta signalling in health and disease. Nat Genet 2004, 36:790-792.
82. Derynck R., Zhang Y.E. Smad dependent and Smad independent pathways in TGF beta family signalling. Nature 2003, 425:577-584.
83. Trobridge P., Knoblaugh S., Washington M.K., Munoz N.M., Tsuchiya K.D., Rojas A. TGF beta receptor inactivation and mutant KRAS induce intestinal neoplasms in mice via a beta catenin independent pathway. Gastroenterology 2009 May, 136(5):1680-1688.
84. Ogino S., Kawasaki T., Ogawa A., Kirkner G.J., Loda M., Fuchs C.S. TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability high colorectal cancer. Hum Pathol 2007 Apr, 38(4):614-620.
85. Gulubova M., Manolova I., Ananiev J., Julianov A., Yovchev Y., Peeva K. Role of TGF beta 1, its receptor TGFbetaRII and Smad proteins in the progression of colorectal cancer. Int J Colorectal Dis 2010 May, 25(5):591-599.
86. Popat S., Houlston R.S. A systematic review and meta analysis of the relationship between chromosome 18q genotype, DCC status and colorectal prognosis. Eur J Cancer 2005, 41:2060-2070.
87. Kern A., Taubert H., Scheele J., Rudroff C., Mothes H., Kappler M., et al. Association of p53 mutations, microvessel density and neoangiogenesis in pairs of colorectal cancers and corresponding liver metastases. Int J Oncol 2002 Aug, 21(2):243-249.
88. Molchadsky A., Rivlin N., Brosh R., Rotter V., Sarig R. p53 is balancing development, differentiation and de-differentiation to assure cancer prevention. Carcinogenesis 2010 Sep, 31(9):1501-1508.
89. Sakasai R., Teraoka H., Takagi M., Tibbetts R.S. Transcription-dependent activation of ataxia telangiectasia mutated prevents DNA-dependent protein kinase-mediated cell death in response to topoisomerase I poison. J Biol Chem 2010 May 14, 285(20):15201-15208.
90. Farnebo M., Bykov V.J., Wiman K.G. The p53 tumor suppressor: a master regulator of diverse cellular processes and therapeutic target in cancer. Biochem Biophys Res Commun 2010 May 21, 396(1):85-89.
91. Lo H.W. Nuclear mode of the EGFR signalling network: biology, prognostic value and therapeutic implications. Discov Med 2010 Jul, 10(50):44-51.
92. Saif M.W. Colorectal cancer in review: the role of the EGFR pathway. Expert Opin Investig Drugs 2010 Mar, 19(3):357-369.
93. Roda J.M., Joshi T., Butchar J.P., McAlees J.W., Lehman A., Trindandapani S., et al. The activation of natural killer cell effector functions by cetuximab coated, epidermal growth factor receptor positive tumour cells is enhanced by cytokines. Clin Cancer Res 2007, 13:6419-6428.
94. Bansal A., Liu X., McGregor D.H., Singh V., Hall S. Correlation of epidermal growth factor receptor with morphological features of colorectal advanced adenomas: a pilot correlative case series. Am J Med Sci 2010 Oct, 340(4):296-300.
95. Shankaran V., Obel J., Benson A.D. Predicting response to EGFR inhibitors in metastatic colorectal cancer: current practice and future directions. Oncologist 2010, 15(2):157-167.
96. Winawer S.J. -The multidisciplinary management of gastrointestinal cancer. Colorectal cancer screening. Best Pract Res Clin Gastroenterol 2007, 21(6):1031-1048.
97. Booth R.A. -Minimally invasive biomarkers for detection and staging of colorectal cancer. Cancer Lett 2007 Apr 28, 249(1):87-96.
98. White V., Scarpini C., Barbosa-Morais N.L., Ikelle E., Carter S., Laskey R.A., et al. -Isolation of stool-derived mucus provides a high yield of colonocytes suitable for early detection of colorectal carcinoma. Cancer Epidemiol Biomarkers Prev 2009 Jul, 18(7):2006-2013.
99. Bedi A., Pasricha P.J., Akhtar A.J., Barber J.P., Bedi G.C., Giardiello F.M., et al. Inhibition of apoptosis during development of colorectal cancer. Cancer Res 1995 May 1, 55(9):1811-1816.
100. Boynton K.A., Summerhayes I.C., Ahlquist D.A., Shuber A.P. DNA integrity as a potential marker for stool-based detection of colorectal cancer. Clin Chem 2003 Jul, 49(7):1058-1065.
101. Kim H.J., Yu M.H., Kim H., Byun J., Lee C. Noninvasive molecular biomarkers for the detection of colorectal cancer. BMB Rep 2008 Oct 31, 41(10):685-692.
102. Oliveira C., Velho S., Moutinho C., Ferreira A., Preto A., Domingo E., et al. KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression. Oncogene 2007 Jan 4, 26(1):158-163.
103. Calistri D., Rengucci C., Seymour I., Lattuneddu A., Polifemo A.M., Monti F., et al. -Mutation analysis of p53, K-ras, and BRAF genes in colorectal cancer progression. J Cell Physiol 2005 Aug, 204(2):484-488.
104. Fakih M.G., Padmanabhan A. CEA monitoring in colorectal cancer. What you should know. Oncology 2006 May, 20(6):579-587.
105. Tan E., Gouvas N., Nicholls R.J., Ziprin P., Xynos E., Tekkis P.P. Diagnostic precision of carcinoembryonic antigen in the detection of recurrence of colorectal cancer. Surg Oncol 2009 Mar, 18(1):15-24.
106. Imperiale T.F., Ransohoff D.F., Itzkowitz S.H., Turnbull B.A., Ross M.E. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 2004 Dec 23, 351(26):2704-2714.
107. Ahlquist D.A., Sargent D.J., Loprinzi C.L., Levin T.R., Rex D.K., Ahnen D.J., et al. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med 2008 Oct 7, 149(7):441-450. W81.
108. Ogino S., Kirkner G.J., Nosho K., Irahara N., Kure S., Shima K., et al. Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer. Clin Cancer Res 2008 Dec 15, 14(24):8221-8227.
109. Soumaoro L.T., Uetake H., Higuchi T., Takagi Y., Enomoto M., Sugihara K. Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res 2004 Dec 15, 10(24):8465-8471.
110. Ogino S., Nosho K., Kirkner G.J., Kawasaki T., Meyerhardt J.A., Loda M., et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009 Jan, 58(1):90-96.
111. Malesci A., Laghi L., Bianchi P., Delconte G., Randolph A., Torri V., et al. Reduced likelihood of metastases in patients with microsatellite-unstable colorectal cancer. Clin Cancer Res 2007 Jul 1, 13(13):3831-3839.
112. Chang S.C., Lin J.K., Yang S.H., Wang H.S., Li A.F., Chi C.W. Relationship between genetic alterations and prognosis in sporadic colorectal cancer. Int J Cancer 2006 Apr 1, 118(7):1721-1727.
113. Russo A., Bazan V., Agnese V., Rodolico V., Gebbia N. Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies. Ann Oncol 2005 May, 16(Suppl 4):iv44-iv49.
114. Popat S., Hubner R., Houlston R.S. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005 Jan 20, 23(3):609-618.
115. Deschoolmeester V., Baay M., Specenier P., Lardon F., Vermorken J.B. A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy. The Oncologist 2010, 15:699-731.
116. Lombardi L., Morelli F., Cinieri S., Santini D., Silvestris N., Fazio N., et al. Adjuvant colon cancer chemotherapy: where we are and where we'll go. Cancer Treat Rev 2010 Nov, 3(Suppl. 36):S34-S41.
117. Heinemann V., Stintzing S., Kircher T. Clinical relevance of EGFR and KRAS status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. Cancer Treat Rev 2008, 35:262-271.
118. Laurent P., Cayre A., Manceau G. Analysis of PTEN, BRAF and EGFR status in determining benefit from cetuximab therapy in wild type KRAS metastatic colon cancer. J Clin Oncol 2009, 27:5924-5930.
119. Pommier Y. DNA topoisomerase I inhibitors: chemistry, biology and interfacial inhibition. Chem Rev 2009 July, 109(7):2894-2902.
120. Valbohmer D., Iqbal S., Yang D.Y., et al. Molecular determinants of irinotecan efficacy. Int J Cancer 2006, 119:2435-2442.
121. Braun M.S., Richman S.D., Quirke P. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol 2008, 26:2690-2698.
122. Daly A.K. Pharmacogenetics and human genetic polymorphisms. Biochem J 2010 Jul 14, 429(3):435-449.
123. Gibson T.B. -Polymorphisms in the thymidylate synthase gene predict response to 5-fluorouracil therapy in colorectal cancer. Clin Colorectal Cancer 2006 Jan, 5(5):321-323.
124. Pohl A., Lenz H.J. Individualization of therapy for colorectal cancer based on clinical and molecular parameters. Gastrointest Cancer Res 2008 Jul, 2(Suppl. 4):S38-S41.